Thyroid Carcinoma Clinical Trial
Official title:
Investigating Absorbed Radiation Dose Delivered to Differentiated Thyroid Cancer Metastases Following Administration of Fixed Activity of Radioactive Iodine
The main purpose of the study is to establish a relationship between the administered activity of the radioiodine and absorbed dose in the tumor sites.
Status | Recruiting |
Enrollment | 10 |
Est. completion date | July 2010 |
Est. primary completion date | January 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - age above 18 - histological confirmation of the differentiated thyroid carcinoma available - WHO performance score 0-2 - metastatic sites lung and/or bone and/or nodal (radiologically measurable disease > 1 cm) - life expectancy > 6 months - patient has undergone total/near total thyroidectomy - no past history of sensitivity/reaction to 1311 Exclusion Criteria: - non iodine concentrating tumours - received chemotherapy or radiotherapy in 6 weeks - pregnant or breast feeding patients - iodine contrast injection in last 3 months |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
United Kingdom | Royal Marsden NHS Foundation Trust | London | Sutton |
Lead Sponsor | Collaborator |
---|---|
Royal Marsden NHS Foundation Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary outcome measure is to correlate the predicted dose from the tracer study with the actual absorbed dose measure on the therapeutic scan | |||
Secondary | The secondary outcomes will be to assess the response at 6 months post therapy in each patient |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02658513 -
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
|
||
Withdrawn |
NCT01707056 -
The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma
|
N/A | |
Completed |
NCT00215605 -
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT06439745 -
More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
|
||
Terminated |
NCT04327999 -
Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System
|
Phase 2 | |
Completed |
NCT02194920 -
Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function
|
N/A | |
Enrolling by invitation |
NCT06095362 -
Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW
|
Phase 1 | |
Not yet recruiting |
NCT05949424 -
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
|
Phase 4 | |
Active, not recruiting |
NCT02145143 -
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
|
N/A | |
Terminated |
NCT01865838 -
A Study Into the Effect of Seprafilm in Open Total Thyroidectomy
|
N/A | |
Enrolling by invitation |
NCT04411290 -
Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
|
||
Completed |
NCT01813136 -
Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
|
Phase 2 | |
Recruiting |
NCT05668962 -
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
|
Phase 2 | |
Active, not recruiting |
NCT02185560 -
Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
|
||
Completed |
NCT04462471 -
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
|
Phase 1 | |
Completed |
NCT01433809 -
Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm
|
N/A | |
Recruiting |
NCT00929318 -
Influence of Thyroid Hormones on the Woundhealing Process
|
N/A | |
Completed |
NCT05178186 -
Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer
|
N/A | |
Completed |
NCT02773667 -
Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine
|
||
Not yet recruiting |
NCT00993837 -
Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma
|
N/A |